Crackdown On Anti-Cancer Drugs Making Unit For Not Following Norms

Hyderabad: A drug manufacturing unit involved in production of anti-cancer injections as well as antibiotics without following the prescribed norms — was busted by the officials of Drugs Control Administration (DCA) on Wednesday.

The production unit was found making anti-cancer drug cyclophosphamide injection illegally during the raid conducted on Indian Genomix Pvt. Ltd at Cherlapally.

The company was involved in manufacturing cytotoxic, anti-cancer drugs as well as antibiotic injections. Without following the good manufacturing practices (GMPs) guidelines, these two types of drugs were being made at the same facility posing a major risk of cross-contamination of medicines. The production unit was not following the norms and thereby posing a serious health risk, DCA DG V.B. Kamalasan Reddy stated in a press statement on Wednesday.

The cytotoxic anti-cancer drug ‘cyclophosphamide injection’ alters the genetic material (DNA and RNA) of the cells and hence checks the growth or replication of cancer cells. It is used in providing chemotherapy to cancer patients and can cause severe side-effects, Kamalasan Reddy added.

The cytotoxic anti-cancer drugs should be manufactured at a separate, dedicated and self-contained production facility and as per the good manufacturing practices (GMPs) guidelines, so as to ensure a clear-cut separation of cytotoxic substances from other general drugs; otherwise ‘cross-contamination’ of general drugs with ‘cytotoxic anti-cancer drugs’ might lead to serious health consequences in a patient who is not suffering from cancer, he said.

A dedicated facility for handling cytotoxic drugs is crucial and Indian Genomix Pvt. Ltd. located at IDA Cherlapally was not following the norms while producing the anti-cancer drug. The drug manufacturing unit did have the requisite license for making anti-cancer drugs. The company was involved in manufacturing antibiotic injections, together with anti-cancer drugs posing a serious medical hazard, said the DG.

Related Posts

Kota Maternal Deaths: Jaipur Expert Team Finds Sterilization and Fumigation Lapses; FDA Collects Samples, Collector Orders Action

Jaipur:  The investigation into the deaths and critical illness of women following Caesarean deliveries at Kota’s government hospital has intensified, with a high-level medical team from Jaipur reportedly identifying serious…

Prescription Drug Diversion Crisis Deepens Across India: Massive Seizures of Pregabalin, Tramadol, Codeine Syrup and Psychotropic Capsules Expose Regulatory Failure

New Delhi: Despite stringent provisions under the Drugs and Cosmetics Act, 1940 and the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, illegal diversion and trafficking of prescription medicines continues…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Kota Maternal Deaths: Jaipur Expert Team Finds Sterilization and Fumigation Lapses; FDA Collects Samples, Collector Orders Action

Kota Maternal Deaths: Jaipur Expert Team Finds Sterilization and Fumigation Lapses; FDA Collects Samples, Collector Orders Action

Prescription Drug Diversion Crisis Deepens Across India: Massive Seizures of Pregabalin, Tramadol, Codeine Syrup and Psychotropic Capsules Expose Regulatory Failure

Prescription Drug Diversion Crisis Deepens Across India: Massive Seizures of Pregabalin, Tramadol, Codeine Syrup and Psychotropic Capsules Expose Regulatory Failure

US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

Six Women Develop Serious Complications After C-Section

Six Women Develop Serious Complications After C-Section

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected